A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Sponsor
Bristol-Myers Squibb
Study ID
NCT02828124
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986183 — BIOLOGICAL
    specified dose on specified days
  • Nivolumab — BIOLOGICAL
    specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

Key Dates

Start date
Aug 23, 2016
Status verified
Jan 2019
Primary completion
Jan 8, 2018
Completion
Jan 8, 2018

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation Monotherapy
  • Experimental: Dose Expansion Monotherapy
  • Experimental: Dose Escalation Combination Therapy
  • Experimental: Dose Expansion Combination Therapy

Primary Outcome Measure

Incidence of Adverse Events at Its Worst Grade [ Time Frame: First dose up to approximately 24 months ]

Related Studies